Top 5 Drug Type | Count |
---|---|
Diagnostic radiopharmaceuticals | 4 |
Monoclonal antibody | 2 |
Prophylactic vaccine | 1 |
Radiolabeled antibody | 1 |
Dendritic cell vaccine | 1 |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date18 May 2016 |
Target- |
Mechanism Cell replacements |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2025 |
Sponsor / Collaborator |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Rilparencel | Chronic Kidney Diseases More | Phase 3 |
[18F]-MC-225 ( P-gp ) | Mild cognitive disorder More | Phase 2 Clinical |
[89Zr]Zr-Df-Crefmirlimab ( CD8 ) | Locally Advanced Malignant Solid Neoplasm More | Phase 2 |
Atezolizumab ( PDL1 ) | Head and Neck Neoplasms More | Phase 2 |
Bevacizumab-IRDye800CW(University of Groningen) ( VEGF-A ) | Age Related Macular Degeneration More | Phase 1 |